Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR -Mutated NSCLC

ConclusionsPre-treatmentEGFR copy number gain determined by amplicon-based next generation sequencing data predicts worse overall survival inEGFR-mutated patients treated with first-line EGFR-tyrosine kinase inhibitors. T790M at relapse and subsequent treatment with osimertinib predict longer overall survival.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research